▼ scroll down to learn more ▼
UCC VICAN I Limited Partnership (the “Company”), began operations on April 20, 2020 as a special purpose entity formed with the sole purpose of making an investment into United Cancer Centers, Inc. (“UCC”) by way of purchasing preferred shares of stock issued by UCC. A certain percentage of invested capital will also be used for investment grade zero coupon bonds, bank instruments, and insurance products. The Company’s legal structure was formed as a limited partnership under the laws of the State of Wyoming on October 26, 2019. The General Partner of the Company is Vivaris Capital, LLC (the “General Partner” or the “GP”) and the individual manager is J. Christopher Mizer.
UCC is currently executing an offering of Class A Preferred Stock in United Cancer Centers, Inc. representing a five percent (5%) stake of the cash revenues (less returns and allowances) generated by the United Cancer Center’s Right-to-Try clinic network. United Cancer Centers, Inc. is launching U.S.-based outpatient clinics that seek to redefine the concept of informed decision making for cancer patients by providing access to a wider array of both FDA-approved and investigational treatment options. UCC VICAN I Limited Partnership will also invest in a portfolio of investment grade, zero coupon bonds to assist in securing the return of the principal invested amount at the end of ten years.
UCC comprises a collection of U.S.-based outpatient clinics that seek to redefine the concept of informed decision making for cancer patients by providing access to a wider array of both FDA-approved and investigational treatment options. The mission of United Cancer Centers is to provide comprehensive cancer treatment that address the glaring issues faced by cancer patients, such as the need for information regarding treatment options, access to investigational therapies once all standard of care options are exhausted, and the affordability of care.
UCC expects to be the first comprehensive cancer treatment facility that assists patients in navigating the federal Right-to-Try legislation, which provides terminally ill patients the ability to be treated with promising and safe drugs still in clinical development. United Cancer Centers will work to identify and source promising breakthrough technologies that can be accessed under the Right-to-Try legislation.
United Cancer Centers plans to take a process that typically takes 10 to 15 years with the U.S. FDA and to time collapse this into as little as 18 months. By shortening the gap between scientific discovery and implementation, UCC intends to provide patients with a feasible and understandable pathway to the most cutting edge therapeutic interventions.
UCC’s hope is that this process can better facilitate the pathway to a cure for cancer.
The Company is currently managed by seasoned business and sector professionals dedicated to the success of the Company and efficient execution of its planned operations.
Christopher is the founder of Vivaris Capital, LLC and has over 25 years of executive management and corporate finance experience. He previously served as a Senior Accountant with Ernst & Young and Vice President of the investment banking division of Key Capital Markets. He earned the B.S. and M.S. degrees (biology), B.A. (economics), and MBA (accounting and finance) degrees from Case Western Reserve University.
Chief Executive Officer and General Counsel
nearly 20 years, Ken provided legal representation to several of the largest providers of institutional healthcare in the United States. In that capacity, Ken’s primary focus was as trial counsel in medical malpractice cases defending all manner of care providers in Federal and State courts as well as before various licensing and review boards on behalf of individual practitioners. In addition, he routinely consulted on policy and procedure formation, regulatory compliance, bylaw development, staff in-servicing and risk reduction strategies. Ken has lectured frequently at the national gatherings of institutional healthcare providers. Ken honed his counseling, litigation and management skills as a partner and shareholder in a national law firm where he opened and managed multiple offices as part of the firm’s regional operations n California and Wyoming. Ken is excited to bring nearly two- decades of experience at the intersection of law and healthcare to benefit patients and support the advancement of investigational medicine. Ken Webster has a full time commitment to United Cancer Centers.
As past president of the Society for the Immunotherapy of Cancer and Editor- in-Chief of the Journal of Translational Medicine and with over 600 peer- reviewed scientific papers, Dr. Marincola is considered one of the world’s leading experts in cancer immunotherapy. Dr. Marincola was Distinguished Research Fellow at AbbVie, Inc. He also was Chief Research Officer of Sidra Medical and Research Center in Doha, Qatar. Prior to that, Dr. Marincola was Chief Infectious Disease and Immunogenetics Branch at the U.S. National Institutes of Health. Dr. Marincola earned his M.D. from the University of Milan and completed his clinical training in Surgery and scientific training at Stanford University from 1980 – 1990. Dr. Marincola will have a part time commitment with United Cancer Centers during his time in the position of interim Chief Medical Officer. Following completion of this offering, Dr. Marincola’s commitment is projected to change.
President, UCC Board Member
Ed Clay is a former professional Mixed Martial Arts fighter, at one point, ranked as high as number 9 in the world. He ran one of the largest Mixed Martial Arts schools in the United States with multiple students fighting in events such as the Ultimate Fighting Championships.
His clothing brand, Gameness, which was acquired in 2011, was the largest supplier of Brazilian Jiu-Jitsu Martial Arts uniforms in the world. He was a MMA co-host of a highly rated FM sports radio show for 8 years. He is the former owner and Editor in Chief of Submission Fighter magazine.
In 2015, along with his 2 partners Scott Nelson and Deddrick Perry, Clay acquired the CHIPSA hospital in Tijuana, Mexico. Ed is interested in developing solutions to address some of the glaring issues with cancer management in the United States and is a strong supporter of integrative immunotherapy: the concept of bringing together the conventional and alternative sides of medicine to improves patient outcomes.
Ed is considered a pioneer in the direct response internet marketing space. His vast experience with messaging and online media along with 18 years experience as an entrepreneur gives him a unique skill set as President of United Cancer Centers. Ed Clay has a full time commitment to United Cancer Centers.
Chief Marketing Officer, UCC Board Member
Scott Nelson has a long history dating back to 1984 with programing and technology platforms. Over the years he saw that every business needed good marketing and sales to thrive.
Marketing automation and e-commerce became his passion before his shift in to health care. In 1996, long before it became popular, Scott co-founded one of the first online lifestyle magazines. He was travel blogging before blogs became popular.
He created a life style brand, On The Mat (OTM), by competing himself in martial arts around the world. The site’s popularity allowed him to branch out in to 3 successful lifestyle apparel clothing brands.
Building on the success of the brands he went on to open 13 brick and mortar retail locations. The brands popularity quickly grew and manufacturing outside of the USA became a necessity. Scott then successfully navigated overseas manufacturing garments and hard goods in China, Taiwan, Pakistan, and Brazil.
Scott leveraged his vast experience in manufacturing and marketing to begin consulting, specializing in sourcing niche markets and selling them online. In 2008, he authored a book on launching online brands from development and manufacturing to full online product launch.
Scott has honed his digital marketing skills over the last 23 years, staying ahead of the curve becoming an electronic automation ninja using platforms such as his favorite, InfusionSoft.
He specializes in online sales funnel optimization and lead generation. Currently Scott owns and manages multiple online businesses but his primary passion is fighting cancer and working with UCC.
Scott Nelson is a co-founder and owner of the CHIPSA Hospital where he implemented CHIPSA’s entire patient experience platform from lead, to in hospital and, automated after care follow up. Scott also oversaw the CHIPSA’s ERP system implementation in full compliance with the COFEPRIS (Mexico’s FDA) regulations. Scott Nelson has a full time commitment to United Cancer Centers.
Executive Vice President, UCC Board Member
Deddrick Perry is an investor and entrepreneur with over 9 years of experience as a principal and treasury manager. Deddrick specializes in strategic structuring of assets and managing liquidity across multinational companies and currencies.
Mr. Perry has served on several boards and is a 2015 NLC Fellow and has extensive experience developing political operatives. Prior to 2010, Mr. Perry was a sales coach and consultant in the Chicago advertising industry. Deddrick’s lean management style helps him to effectively grow and scale businesses across a variety of distinct industries.
Deddrick is the Co-Founder and Chief Operating Officer of CHIPSA Hospital and The North Beach Clinic; and principal Co-Founder of FirstMedic Sa.Cv Hospital Corporation and Servicios Medicos Clinical Corporation in Mexico. In this capacity, Deddrick has extensive experience in managing clinical operations and in addition to managing international treasury services for the Company. Furthermore, he has spearheaded the launch of CHIPSA’s first affiliated outpatient facility, establishing the building blocks for the floor plan and buildout model for future United Cancer Center clinics. Deddrick Perry has a full time commitment to United Cancer Centers.
Vice President of Precision Oncology
Vijay Mahant received his MS., Ph.D., and first post-doctorate from LUT (UK), He received his second post-doctorate from the UT Health Science Center at Houston/ MD Anderson, TX, USA). Dr. Mahant is a scientist and an entrepreneur with more than 35 years of experience in immuno-and precision medicine (oncology, cardiology, pain management and psychiatric, etc).
He has held executive positions and he is a founder/co-founder of diagnostic companies, He is currently the CEO of MediLite Diagnostika Inc. Dr. Mahant has been involved in fund raisings, Initial Public Offerings (IPOs) and he has 30 issued patents and 10 patents pending; he has authored and/or co-authored publications in journals and science books; he is an associate editor of Journal of Translation Medicine.
Dr. Mahant has managed intellectual property, including in-and out -licensing. He developed several FDA cleared products with multimillion dollars in revenues. Dr. Mahant is on the SAB/MAB of Batu Biologics (an oncology company), CHIPSA Hospital (an oncology hospital) , Trutino Biosciences (an oncology company and developing an IL2-peptide based drug), TulyNode (an autologous immune therapy company). SNET (an oncology company focused on autologous immuno- therapy and “targeted” drug delivery), Immunicom (immunophoreis device for treating cancer) and APT (focused on preeclampsia). Dr. Mahant has a part time position in United Cancer Centers, contingent upon the raising of capital.
Director of Clinical Data and Innovations
Lindsay Picker currently serves as the Director of Clinical Operations at Moleculin Biotech Inc, a clinical stage pharmaceutical company focused on the treatment of highly resistant cancers with two active clinical stage drugs targeting Acute Myeloid Leukemia, brain tumors and pancreatic cancer. Lindsay played a key role at Moleculin in the advancement of their Immune/Transcription Modulators that is currently in a phase 1 clinical trial at MD Anderson for the treatment of brain tumors with active plans for pediatric brain tumor trial at Emory University.
Lindsay works alongside her father Donald Picker, PhD., the current Chief Scientific Officer at Moleculin, who was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, acquired by Bristol-Myers Squibb and with annual sales of over $500 million.
Prior to Moleculin, Lindsay served as the lead medical monitor and genetic consultant for one of the worlds leading Contract Research Organizations, ICON plc where she was responsible for creating strategic partnership with Pfizer on several Global Oncology trials.
Lindsay is highly knowledgeable in Clinical Trial data collection systems as well as Good Clinical Practices Certified. She earned her Bachelor of Science in Biochemistry from UCSD and obtained her Master of Science in Human Genetics with a concentration in molecular biology and genetics from the Medical College of Virginia.
Chief Process Officer
Dr. Wang was Acting Chief of Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center at the National Institutes of Health (NIH) as well as Associated Director of Trans NIH Center for Human Immunology, Omic Facility Head at the NIH and Director of Molecular Science in Department of Transfusion Medicine (DTM), Clinical Center, NIH. She was also Adjunct Professor Peking Union Medical College, Beijing, China; Adjunct Professor Shanghai Medical College, Fudan University, Shanghai China, and Adjunct Professor Southern Medical University, Guangzhou, China. Earlier in her career she was Cancer Research Fellow – Surgery Branch, National Cancer Institute, NIH and Assistant Research Scientist, Arizona Cancer Center, University of Arizona, Tucson, Arizona.
- cancer.org | "Facts & Figures 2019: US Cancer Death Rate has Dropped 27% in 25 Years", Stacy Simon, January 8, 2019
Minimum Offering: $10,000,000
Minimum Subscription: $10,000 (10 Units)
The Company is offering a minimum of 10,000 and a maximum of 100,000 Limited Partnership Units at a price of $1,000 per Unit. Upon completion of the Offering, between 10,000 and 100,000 Limited Partnership Units will be issued.
Assuming the Company raises the maximum offering amount, and deploys such capital, in part, into the Preferred Shares of UCC, then the Company shall receive five percent (5%) of the net revenues of UCC in the form of a Preferred Divided.
TThe Limited Partnership Units sold through this Offering shall participate in distributions of net profits from the Company’s operations and investments as follows: (i) an annual, six percent (6%) non-compounding, cumulative Preferred Return distribution (the “Preferred Return”) distributed to Limited Partners quarterly and calculated based on the Limited Partner’s invested capital contributions and; (ii) one hundred percent (100%) of distributable net profit from operations to the Limited Partners until such time as any accrued Preferred Return is paid and; (iii) a distribution to the Limited Partners on a pari passu basis equaling eighty percent (80%) of any additional net income from operations of the Company with the General Partner participating in twenty percent (20%) and; (iv) one hundred percent (100%) of the proceeds from the redemption of UCC issued Preferred Shares until such time as invested capital proceeds from Limited Partners have been repaid; and (v) a distribution to the Limited Partners on a pari passu basis equaling eighty percent (80%) of any additional proceeds from the redemption of the UCC Preferred Shares with the General Partner participating in twenty percent (20%).
Please complete the contact form and we will get back to you about any questions you have about our offering.
UCC VICAN I Limited Partnership - 53 Calle Palmeras Suite 601 - San Juan 00901, PR — email@example.com — (619) 727-8497
The UCC VICAN I Limited Partnership 506(c) Investor Portal provides the opportunity to learn about our investment opportunity. Once registered, you will have:
Once your account is upgraded you will have additional access including: